$DJI 0.13% NDX 0.46% SPX 0.26% VIX 1.57% News *
Wed, Sep 18 1:11am

BIIB $238.70 2.58 (1.09%)
Biogen Inc

BIIB Profile

Market Cap 43.52 Billion
BIIB Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Visit Website

BIIB Earnings

EPS 7.85 P/E Ratio 10.77
Previous Wed, Apr 24, 2019
Latest Tue, Jul 23, 2019 (57 days ago) +2.68%

BIIB Dividend

Yield --
Ex-Date --
Pay Date --
History --

BIIB Charts

1 Year
Mar 22, 2019
Sep 27, 2018

Symbol Price Day Δ YTD Δ
BIIB $238.70 1.09% -21.66%


Symbol Surfing

How can we make Symbol Surfing better?


Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy